Changeflow GovPing Federal Courts Walgreen Co. v. Collegium Pharmaceutical, Inc. ...
Routine Enforcement Removed Final

Walgreen Co. v. Collegium Pharmaceutical, Inc. - Motion to Dismiss

Favicon for www.courtlistener.com NDIL Opinions
Filed February 18th, 2026
Detected March 5th, 2026
Email

Summary

The District Court for the Northern District of Illinois granted Collegium Pharmaceutical's motion to dismiss a case filed by Walgreen Co. The court found a lack of personal jurisdiction and failure to state a claim regarding alleged breaches of a return policy for pain medications. The case involved claims of over $14 million in unjust enrichment.

What changed

The District Court for the Northern District of Illinois has granted a motion to dismiss filed by Collegium Pharmaceutical, Inc. in the case Walgreen Co. v. Collegium Pharmaceutical, Inc. (Docket No. 1:25-cv-06560). Walgreen alleged that Collegium frustrated its returns of pain medications, breaching a return policy and leading to unjust enrichment exceeding $14 million. The court's decision was based on a lack of personal jurisdiction under Rule 12(b)(2) and failure to state a claim under Rule 12(b)(6).

This ruling dismisses Walgreen's claims against Collegium. While the document is a court opinion, it does not impose new regulatory requirements or deadlines on regulated entities. The primary implication is for the parties involved in this specific litigation. No further action is required from other pharmaceutical companies or retailers based on this ruling, as it pertains to jurisdictional and claim-specific legal standards.

Source document (simplified)

Jump To

Top Caption Trial Court Document The text of this document was obtained by analyzing a scanned document and may have typos.

Support FLP

CourtListener is a project of Free
Law Project
, a federally-recognized 501(c)(3) non-profit. Members help support our work and get special access to features.

Please become a member today.

Join Free.law Now

Feb. 18, 2026 Get Citation Alerts Download PDF Add Note

Walgreen Co. v. Collegium Pharmaceutical, Inc.

District Court, N.D. Illinois

Trial Court Document

UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF ILLINOIS

EASTERN DIVISION

WALGREEN CO.,

      Plaintiff,                                                     
                                  No. 25 CV 6560                     
  v.                                                                 
                                  Judge Manish S. Shah               

COLLEGIUM PHARMACEUTICAL, INC.,

      Defendant.                                                     

             MEMORANDUM OPINION AND ORDER                            

Plaintiff Walgreens purchased prescription medications through a wholesale 

distributor. This distributor contracted with defendant Collegium Pharmaceutical for
the purchase of certain pain medications. Pursuant to Collegium’s return policy,
Walgreens used a reverse distribution company to return unused medication.
Walgreens alleges that Collegium frustrated its returns, thus breaching the return
policy, or, alternatively, leading to unjust enrichment in excess of $14 million.
Defendant moves to dismiss under Rule 12(b)(2) for lack of personal jurisdiction and
Rule 12(b)(6) for failure to state a claim. For the reasons discussed below, defendant’s
motion to dismiss is granted.

I. Legal Standards

Federal Rule of Civil Procedure 12(b)(2) governs dismissals based on lack of
personal jurisdiction. When a defendant challenges jurisdiction under Rule 12(b)(2),
“the plaintiff bears the burden of demonstrating the existence of jurisdiction.” NBA
Props., Inc. v. HANWJH, 46 F.4th 614, 620 (7th Cir. 2022). If the decision is based
solely on written materials without an evidentiary hearing, the plaintiff need only
make a prima facie showing of personal jurisdiction over the defendant. Matlin v.
Spin Master Corp., 921 F.3d 701, 705 (7th Cir. 2019). All well-pleaded facts alleged

in the complaint are taken as true and any factual disputes are resolved in plaintiff’s
favor. Id. II. Background

Plaintiff Walgreen Co. provides consumer goods as well as pharmacy services
through thousands of retail drugstores throughout the United States. [1] ¶ 3.1
Walgreens is an Illinois corporation with its principal place of business in Illinois. [1]

¶ 3. Defendant Collegium Pharmaceutical Inc. develops and commercializes
medications. [1] ¶ 4. Collegium is a Virginia corporation with its principal place of
business in Massachusetts. [1] ¶ 4.2

Prescription medications are unusable after their expiration date. [1] ¶ 8.
Manufacturers typically provide for the return or destruction of medications after or
near expiry. [1] ¶ 8. The process of returning and receiving refunds or credits for
expired or expiring pharmaceuticals is known as reverse distribution. [1] ¶ 8. Third-

party reverse distribution companies facilitate the return process. [1] ¶ 9.

1 Bracketed numbers refer to entries on the district court docket and page numbers are taken
from the CM/ECF header placed at the top of the filing. The facts are taken from the
complaint, [1]; the evidence submitted by defendant in opposition to the exercise of
jurisdiction, [9-1], [9-2], [9-3], [9-4], [9-5], and [9-6]; and the evidence submitted by plaintiff
in response and in support of the exercise of jurisdiction, [16-1], [16-2], [16-3], and [16-4].
2 The court has subject-matter jurisdiction over this case because the parties are diverse in
citizenship and the amount in controversy exceeds $75,000. [1] ¶¶ 3–5; 28 U.S.C. § 1332 (a)(1).
Walgreens bought many prescription medications through a wholesale
distributor. [1] ¶ 13.3 Walgreens’s distributor contracted with Collegium for the
purchase of certain medications, which it then resold to Walgreens. [1] ¶ 14.

Walgreens has purchased medications from Collegium through its distributor since
2017. [1] ¶ 17.

Collegium published a return policy that allowed the return of medications it
manufactured. [1] ¶ 18. This return policy was provided to Walgreens, who bought
millions of dollars of medications in reliance on the policy. [1] ¶ 19. Collegium’s return
policy allowed pharmacies to return the products that they purchased through a

distributor. [1] ¶ 23; [9-2] at 2. The policy specifically required that returnable
products be sent to Collegium’s reverse distribution company in Kentucky. [1] ¶ 25.4
Walgreens used its own reverse distribution company to return unused prescription
medications, [1] ¶ 32.5

Employees from Walgreens and Collegium exchanged hundreds of emails and
met in Illinois on many occasions to discuss two medications that Walgreens
purchased from Collegium. [16-2] ¶ 4. Some of these emails discussed Collegium’s

return policy. See [16-2].

3 Cencora, Inc., Walgreens’s wholesale distributor, is a Pennsylvania corporation with its
principal place of business in Pennsylvania. [9-1] ¶ 4; [9-4].

4 Integrated Commercialization Solutions, LLC, Collegium’s reverse distribution company, is
a California company with its principal place of business in Texas. [9-1] ¶ 8; [9-5]. The
citizenship of ICS’s members is not mentioned by either party.

5 Inmar RX Solutions, Inc., Walgreens’s reverse distribution company, is a Texas corporation
with its principal place of business in North Carolina. [9-6].

Walgreens alleges that Collegium, through its reverse distributor, “began to
frustrate and make it impossible” for Walgreens to return medications consistent
with the terms of the return policy. [1] ¶ 37. Plaintiff claims that the return policy is

a valid and enforceable contract and filed the present case alleging that defendant
has breached this contract by failing to provide credit for plaintiff’s returns. [1] ¶¶ 52–
60. In the alternative, plaintiff brings a claim for unjust enrichment. [1] ¶¶ 61–64.

III. Analysis

Defendant moves to dismiss on two separate grounds. First, Collegium argues
that the court lacks personal jurisdiction over it. In the alternative, defendant argues

that even if personal jurisdiction were present, dismissal is nonetheless appropriate
because plaintiff failed to state a claim under Rule 12(b)(6).

“A district court sitting in diversity has personal jurisdiction over a
nonresident defendant only if a court of the state in which it sits would have
jurisdiction.” Purdue Rsch. Found. v. Sanofi-Synthelabo, S.A., 338 F.3d 773, 779 (7th
Cir. 2003). The Illinois long-arm statute confers personal jurisdiction if “permitted by
the Illinois Constitution and the Constitution of the United States.” 735 ILCS 5/2-

209(c); see also J.S.T. Corp. v. Foxconn Interconnect Tech. Ltd., 965 F.3d 571, 575 (7th
Cir. 2020). Thus, the question is whether exercising personal jurisdiction on
Collegium “comports with the limits imposed by federal due process.” Walden v. Fiore, 571 U.S. 277, 283 (2014).

Federal due process requires that a defendant have minimum contacts with
the forum state “such that the maintenance of the suit does not offend ‘traditional
notions of fair play and substantial justice.’” Int’l Shoe Co. v. Washington, 326 U.S.
310, 316
(1945) (citations omitted). For cases alleging a breach of contract,
“contracting with an out-of-state party alone cannot establish automatically

sufficient minimum contacts in the other party’s home forum.” Purdue Rsch., 338
F.3d at 781
(citing Burger King Corp. v. Rudzewicz, 471 U.S. 462, 478 (1985)). Rather,
Illinois courts consider a variety of factors, including who initiated the transaction,
where the contract was negotiated, where the contract was formed, and where
performance of the contract was to take place. See Philos Techs., Inc. v. Philos & D,
Inc., 802 F.3d 905, 913 (7th Cir. 2015).

Plaintiff  asserts  that  both  general  and  specific  jurisdiction  exist  over 

defendant. [16] ¶ 8–9. General jurisdiction exists only where a defendant has
“continuous and systematic general business contacts” with the forum. uBID, Inc. v.
GoDaddy Grp., Inc., 623 F.3d 421, 425 (7th Cir. 2010) (quoting Helicopteros
Nacionales de Colombia, S.A. v. Hall, 466 U.S. 408, 415–16 (1984)). Specific
jurisdiction exists when defendant’s “suit-related conduct creates a substantial
connection with the forum state.” Walden, 571 U.S. at 284.

A.   General Jurisdiction                                            
Walgreens alludes to general personal jurisdiction over Collegium because 

“Collegium’s Illinois contacts are systematic and continuous.” [16] at 8. But to
establish general jurisdiction, Walgreens must show that Collegium’s contacts with
Illinois are so extensive that Collegium “can be treated as present in the state for
essentially all purposes.” uBid, 623 F.3d at 425–26. Collegium is neither incorporated
in nor has its principal place of business in Illinois. Developing medications that may
be distributed across the country does not mean that a company subjects itself to
general personal jurisdiction in every state that it sends products (through

intermediary distributors) to. Just because Collegium has some dealings in Illinois
(whether through Walgreens or other potential customers) does not mean it is “at
home” in Illinois for purposes of general jurisdiction. See Daimler AG v. Bauman, 571
U.S. 117
, 133 n.11 (2014) (noting that a corporation’s affiliation with the forum state
must be “comparable to a domestic enterprise in that State” for general jurisdiction
to exist). This court does not have general personal jurisdiction over Collegium.

B.   Specific Jurisdiction                                           
Specific jurisdiction, by contrast, does not require systematic contacts with the 

forum state. Instead, specific jurisdiction analyzes the connection between the
defendant, the forum, and the underlying controversy. See Curry v. Revolution Lab’ys,
LLC, 949 F.3d 385, 395 (7th Cir. 2020). Jurisdiction is proper when the defendant
takes some act by which it “purposefully avails itself of the privilege of conducting
activities with the forum State.” Ford Motor Co. v. Mont. Eighth Jud. Dist. Ct., [592

U.S. 351, 359](https://www.courtlistener.com/opinion/4867543/ford-motor-co-v-montana-eighth-judicial-dist/#359) (2021). The defendant’s contacts with the forum state must be its own
choice and not random or fortuitous. Id. And the litigation must arise out of or relate
to those contacts. B.D. ex rel. Myer v. Samsung SDI Co., 91 F.4th 856, 861 (7th Cir.
2024).

Walgreens contends that Collegium is subject to specific jurisdiction in Illinois
because Walgreens purchased the products at issue as a “direct result of years-long,
continuous outreach by Collegium to Walgreens.” [16] at 8. Walgreens cites hundreds
of communications directed to Walgreens in Illinois, meetings in Illinois, and a data
license agreement between the parties governed by Illinois law as evidence of

Collegium purposefully availing itself to the privilege of conducting business in
Illinois. [16] at 8. But “in a breach of contract case, it is only the dealings between the
parties in regard to the disputed contract that are relevant to minimum contacts
analysis.” Felland v. Clifton, 682 F.3d 665, 674 (7th Cir. 2012) (emphasis in original)
(quoting RAR, Inc. v. Turner Diesel, Ltd., 107 F.3d 1272, 1278 (7th Cir. 1997)). Thus,
plaintiff’s declarations and exhibits that relate more broadly to Collegium’s

marketing practices, purchase of Walgreens’s inventory data, product placement, and
order history do not establish that Collegium is subject to personal jurisdiction with
respect to the underlying controversy: the return policy.

The attached materials that directly touch upon this disputed (and alleged)
contract do not amount to a prima facie showing of jurisdiction. Walgreens has not
produced any evidence suggesting Collegium’s contacts with Illinois involved
negotiating or forming the return policy. Rather, the emails and phone calls between

the parties took place after the policy existed. See [16-2] ¶ 35 (asking for a copy of the
return policy rather than negotiating its terms); [16-2] ¶ 36 (clarifying the procedures
that must be followed under the policy rather than amending its terms); [16-4] ¶ 7
(flagging that Collegium’s agent was acting untimely rather than asking to modify
the policy). Communicating with Collegium about the subject matter of the return
policy is different from Collegium purposefully directing business activities into the
state where Walgreens is based with an expectation of being haled into Illinois. The
correspondence about the return policy does not suggest that Collegium could
envision continuing and wide-reaching contacts between itself and Illinois at the time

of the policy’s formation. See Burger King, 471 U.S. at 480.

Nor does the parties’ course of dealings after the policy’s formation establish
that Collegium could expect to litigate issues over returns in Illinois. For example,
when providing Walgreens with a copy of the return policy, Collegium noted that the
policy was “for authorized distributors only,” which did not include Walgreens. [16-3]
at 150. In a separate email, Collegium informed Walgreens that it “[does] not have a

return goods policy that covers expired returns from retailers.” [16-3] at 157. And, in
a more recent email, Collegium explained that it was Walgreens’s chosen reverse
distributor that was responsible for complying—and had failed to comply—with the
terms of the return policy. [16-3] at 225. Indeed, the entire email chain provided in
plaintiff’s fourth attachment is titled “Inmar Returns,” further supporting
defendant’s argument that it did not intend to perform under the return policy in the
state where Walgreens was located. See generally [16-4]. Thus, in addition to lacking

evidence that Collegium purposefully availed itself of Illinois law in the formation of
the return policy, Walgreens has also failed to produce evidence that Collegium
expected to perform the return policy in Illinois.

The phone calls and in-person meetings fare no better. Walgreens has not
alleged that Collegium representatives traveled to Illinois to negotiate or form the
return policy. Indeed, Walgreens has been purchasing medications from Collegium
since 2017, and the first mention of a return policy seems to have occurred in January
2018 (after the business relationship between the parties began and presumably after
the return policy was negotiated and formed). See [16-2] ¶ 35.

The ongoing business relationship between the parties over drugs that may 

need to be returned under the policy does not cure the defect. Collegium’s
communications into Illinois to discuss the products, including potential returns,
were about issues with the reverse distributors, who it argues are the proper
beneficiaries of the return policy in the first instance. See [17] at 4; [16-3] at 225
(faulting Inmar for failing to comply with the return policy). Further, a crucial factor

in considering a challenge to personal jurisdiction in a contract case is whether the
defendant initiated contact. See Telco Leasing, Inc. v. Marshall Cnty. Hosp., 586 F.2d
49, 52
(7th Cir. 1978). Here, there is no evidence that Collegium reached out to
Walgreens with respect to the return policy, thus seeking (or expecting) to perform
the contract in Illinois.

Merely contracting with an Illinois corporation is not enough to support
personal jurisdiction. Purdue Rsch., 338 F.3d at 785. And, in contrast to the data

license agreement between the parties, which explicitly called for the application of
Illinois law, there is no such choice of law provision relevant to the instant claim. [16-
3] at 32; see Purdue Rsch., 338 F.3d at 785 (noting that an agreement providing for
the application of a state’s law and contemplating that a substantial portion of the
defendant’s operations would take place in that state is strong evidence of sufficient
minimum contacts). Defendant’s contacts with Illinois are not clearly tied to the
subject matter of this case and are thus insufficient to confer specific personal
jurisdiction. See RAR, 107 F.3d at 1278.6

The alleged breach claimed by Walgreens did not occur in Illinois. Walgreens

alleges that Collegium, through Integrated Commercialization Solutions (not an
Illinois domiciliary), frustrated returns that Walgreens attempted to perform through
Inmar RX Solutions (not an Illinois domiciliary). Collegium’s performance occurred
outside of Illinois. Thus, Walgreens has failed to show that any negotiations,
formation, or breach concerning the disputed contract occurred in Illinois.
Plaintiff has failed to make a prima facie case showing that defendant has

sufficient minimum contacts with Illinois for personal jurisdiction to exist. I therefore
do not reach their arguments for dismissal based on failure to state a claim. See
Kromrey v. U.S. Dep’t of Just., 423 Fed. App’x 624, 626 (7th Cir. 2011) (unless both
subject-matter and personal jurisdiction have been established, a district court must
dismiss the suit without addressing the substance of the plaintiff’s claim).
IV. Conclusion

Collegium Pharmaceutical’s motion to dismiss, [9], is granted for lack of

personal jurisdiction. Plaintiff has leave to file an amended complaint that cures the

6 Neither case cited by plaintiff supports its argument for specific personal jurisdiction.
Kopfman v. Ensign Ribbon Burners, LLC, 803 F.Supp.2d 914 (N.D. Ill. 2011) is a products
liability case that relies on a “stream of commerce” theory of jurisdiction that is inapplicable
in contract cases. See J.S.T. Corp., 965 F.3d at 575–76. Elorac, Inc. v. Sanofi-Aventis Canada
Inc., 2014 WL 7261279 (N.D. Ill. Dec. 19, 2014) supports specific personal jurisdiction over a
contract that was heavily negotiated in the forum state, which is not the case here. Indeed,
Elorac goes on to state that communications into a forum state are insufficient where a
contract was neither performed nor negotiated in the forum. Id. at 8.

jurisdictional defect by March 11, 2026. If no amended complaint is filed, the clerk
will enter judgment terminating the case without prejudice.

ENTER:

                                      Manish 8. Shah 
                                      United States District Judge 

Date: February 18, 2026

                                  11

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
Federal and State Courts
Filed
February 18th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Drug manufacturers Retailers
Geographic scope
National (US)

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Contract Law Jurisdiction

Get Federal Courts alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when NDIL Opinions publishes new changes.

Free. Unsubscribe anytime.